Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85515 trials found · Page 52 of 4276
-
Major trial launches for advanced lung cancer treatment
Disease control Recruiting nowClinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Major trial launches for aggressive stomach cancers
Disease control Recruiting nowThis clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-lin…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC
-
New hope for men with aggressive prostate cancer that stopped responding to other treatments
Disease control Recruiting nowThis is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: t…
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 13, 2026 20:23 UTC
-
New drug trial aims to control aggressive lung cancer
Disease control OngoingThe primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New cancer drug aims to turn tumors back to normal tissue
Disease control Recruiting nowA Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
Phase: PHASE1 • Sponsor: Qurgen Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for aggressive lung cancer: trial tests Dual-Action treatment
Disease control Recruiting nowThe Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Exte…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Breakthrough trial pits new drug combo against standard treatment for advanced lung cancer
Disease control Recruiting nowThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell L…
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Brain infusion trial offers hope for slowing Huntington's disease
Disease control Recruiting nowThe main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Radical cell therapy tested for devastating autoimmune diseases
Disease control Recruiting nowA Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Major trial tests potential new shield against tuberculosis
⭐️ VACCINE ⭐️ Recruiting nowA Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.
Phase: PHASE2 • Sponsor: International AIDS Vaccine Initiative • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 17, 2026 16:12 UTC
-
Immunotherapy before surgery shows promise for advanced skin cancer
Disease control Recruiting nowThis phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may hav…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 24, 2026 06:13 UTC
-
New hope for kids battling tough leukemia: experimental drug combo enters first human trial
Disease control Recruiting nowTo find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New pill aims to slash debilitating pain crises for sickle cell patients
Disease control Recruiting nowThis study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Apr 07, 2026 14:37 UTC
-
New CAR T-Cell therapy targets Tough-to-Treat blood cancer
Disease control Recruiting nowThis is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Can vaccinating and medicating whole villages stop malaria?
Prevention Recruiting nowThis is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the curr…
Phase: PHASE4 • Sponsor: University of Oxford • Aim: Prevention
Last updated Apr 20, 2026 16:14 UTC
-
Experimental immune therapy trial offers hope for HIV patients with Tough-to-Treat lymphoma
Disease control Recruiting nowThis phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to tre…
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New ER program aims to stop opioid overdose deaths with support and medication
Disease control Recruiting nowOpioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patie…
Phase: PHASE1, PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Apr 24, 2026 06:12 UTC
-
New pill challenges standard injection for rare blood disease
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of HSK39297 tablets compared to eculizumab in Patients with PNH who Are Naive to Complement Inhibitor Therapy.
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Scientists test 'Cancer-Killing Virus' in patients with deadly brain tumors
Disease control ENROLLING_BY_INVITATIONClinical study of a novel oncolytic virus Ad-TD-nsIL12 in the treatment of primary high-grade glioma
Phase: PHASE1, PHASE2 • Sponsor: Xiaorong Wu • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
New hope for controlling devastating seizures in severe childhood epilepsies
Disease control ENROLLING_BY_INVITATIONThis (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of …
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC